Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ClearPoint Neuro Inc (CLPT) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance

ClearPoint Neuro IncTrade
Schwab US Dividend Equity ETFTrade

Price performance (Past 24H)

Key statistics

ClearPoint Neuro Inc vs Schwab US Dividend Equity ETF — how do they compare? ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M), while Schwab US Dividend Equity ETF trades at $34.31. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.

CLPTSCHD
Market Cap
$444.14M
Sector
HealthBroad Market / Factor
52-Week High
$29.60$34.27
52-Week Low
$8.66$26.44
Enterprise Value
$478.72M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.

The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.

Schwab US Dividend Equity ETF

SCHD, the Schwab U.S. Dividend Equity ETF, trades at $33.90, up 0.59% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-quality U.S. dividend-paying stocks, offering income stability. Recent news highlights its popularity among retirees for generating passive income, with institutional buying activity noted in Q2 2026 filings.

The outlook for SCHD remains positive for income-focused investors, leveraging dividend growth and low costs. Risks include interest rate sensitivity and market volatility affecting dividend stocks. Analyst sentiment is generally favorable, emphasizing its role in diversified retirement portfolios.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT

About Schwab US Dividend Equity ETF

SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.

Read more on SCHD